WHAT’S NEW – CHANGES SINCE THE 2015 GUIDELINES

9-valent vaccine

9-valent vaccine (Gardasil 9 Seqirus/MSD) is registered for use in females 9–45 years and in males 9–26 years.

HPV9 is funded for both boys and girls aged 9–26 years (inclusive).

Those aged 9–14 years will get a two dose schedule and those aged 15–26 years will receive a three dose schedule.

HPV9 is available (but not funded) up to (and including) age 45 for females.

From 1 January 2017

Funded indications and recommended schedules:

Two doses, at 0 and 6–12 months for individuals aged 9–14 years.

Three doses, at 0, 2 and 6 months, for individuals:

• aged 15–26 years inclusive
• aged 9–26 years inclusive:

– with confirmed HIV infection

– who are transplant (including stem cell) patients

– an additional dose for post-chemotherapy patients

Individuals who started with HPV4 may complete their remaining doses with HPV4 or with HPV9 when available.

Individuals who have previously been fully vaccinated with funded HPV4 are not eligible to receive funded HPV9.

Individuals who have previously been vaccinated with HPV4 which was self-funded are eligible for funded HPV9, up until age 27.

New patient information pamphlet

One new patient information pamphlet is available from the HPV website (www.hpv.org.nz) – Preventing HPV Cancers

By Vaccination: What Everyone Should Know.